RA Capital Management’s Connect Biopharma Holdings CNTB Stock Holding History

RA Capital Management’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,062,871	Closed	-$3.61M	–	77
2023 Q4	$3.61M	Sell	3,062,871 -3,928,132	-56%	-$4.66M	0.06%	59
2023 Q3	$5.73M	Hold	6,991,003	–	–	0.11%	62
2023 Q2	$7.9M	Hold	6,991,003	–	–	0.15%	51
2023 Q1	$6.99M	Hold	6,991,003	–	–	0.16%	53
2022 Q4	$6.07M	Hold	6,991,003	–	–	0.12%	57
2022 Q3	$9.02M	Hold	6,991,003	–	–	0.19%	61
2022 Q2	$6.08M	Hold	6,991,003	–	–	0.16%	69
2022 Q1	$21.1M	Hold	6,991,003	–	–	0.46%	53
2021 Q4	$36M	Hold	6,991,003	–	–	0.63%	47
2021 Q3	$169M	Hold	6,991,003	–	–	2.35%	13
2021 Q2	$137M	Buy	6,991,003 +3,999,795	+134%	+$66.7M	2.19%	9
2021 Q1	$55.3M	Buy	+2,991,208	New	+$50.9M	0.83%	37

Other funds holding CNTB

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

KMWM

Keudell/Morrison Wealth Management Salem, Oregon $529M AUM

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RA Capital Management's CNTB Position: Q1 2024 in Review

RA Capital Management sold out of Connect Biopharma Holdings (CNTB) in Q1 2024, closing a stake of 3,062,871 shares — an estimated $3.61M sold.

RA Capital Management first reported a position in CNTB in Q1 2021 and held it in 12 quarters. The position peaked at $169M in Q3 2021. 12 funds tracked by Wall St. Rank hold CNTB as of Q1 2024.

RA Capital Management reported no remaining Connect Biopharma Holdings position as of Q1 2024 after selling out during the quarter.
RA Capital Management sold 3,062,871 Connect Biopharma Holdings shares in Q1 2024, an estimated $3.61M.
RA Capital Management first reported a position in Connect Biopharma Holdings in Q1 2021 and held it in 12 quarters.
RA Capital Management's Connect Biopharma Holdings position peaked at $169M in Q3 2021.
12 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2024.

Based on RA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.